GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 1,576,240 common shares at a price of $0.27 per share to directors and officers of the company, including 510,000 options granted to Mario Saltarelli, who joined the board as a new director in May 2019 and 391,240 options granted to Deborah Rathjen, President & Chief Executive Officer, in lieu of cash compensation. The options granted to Dr. Rathjen are immediately exercisable, the options granted to Dr. Saltarelli vest over a period of 12 months from the date of grant and the rest of the options, all of which were issued to officers of the company, vest over a period of five years from the date of grant. All of the options expire five years from the date of the grant and are governed by the terms of the company’s stock option plan.
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Deborah Rathjen, Ph.D.
+1 203 533 7082